November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology
Nov 13, 2024, 08:27

Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent paper by Jose Pérez-García, Medical Director of the International Breast Cancer Center, published in Nature Medicine:

“Recommended Nature Medicine read on the promise and challenges of response-adapted trials in breast oncology, with lessons from I-SPY and PHERGain neoadjuvant trials.”

“Moving toward response-adapted trials in oncology”

Authors: Jose Pérez-García, Gabriele Antonarelli, Maria Gion, Antonio Llombart-Cussac and Javier Cortés.

Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology

More posts featuring Paolo Tarantino.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.